CYTK Stock Analysis: Buy, Sell, or Hold?
CYTK - Cytokinetics Inc.
$81.77
-3.10 (-3.65%)
▼
5d:
-4.44%
30d:
+21.92%
90d:
+25.78%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 06, 2026
23d
Smart Money Accumulation
None View Scanner →
Strength: 5.2/10
Get Alerted When CYTK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CYTK shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CYTK shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CYTK is currently trading at $81.77, which is considered slightly high relative to its 30-day fair value range of $72.05 to $85.42.
Technical Outlook: Technically, CYTK is in a strong uptrend. The price is currently testing key support at $80.90. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $107.80 (+27.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CYTK is in a strong uptrend. The price is currently testing key support at $80.90. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $107.80 (+27.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$72.05 -
$85.42
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.6%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.7%)
- BULLISH: Trading 27.0% below Wall St target ($107.80)
Trading Range Analysis
30-Day Trading Range
$72.05 -
$85.42
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$80.90
Resistance Level
$88.31
Current Trend
Strong Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-18.17
Wall Street Target
$107.80
(+27.0%)
Revenue Growth (YoY)
1125.8%
Share & Embed Analysis
Last updated: July 13, 2026 3:35 PM ET
Data refreshes hourly during market hours. Next update: 4:35 PM
Data refreshes hourly during market hours. Next update: 4:35 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CYTK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
16
Sells
Net
INSIDERS SELLING
Recent Transactions
Fady Ibraham Malik
SELL
3500 shares
2026-04-21
Robert I Blum
SELL
7500 shares
2026-04-15
Andrew Callos
SELL
7449 shares
2026-04-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 62 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 67 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 59 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 49 HOLD |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 54 HOLD |
Advanced CYTK Option Strategies
Professional options setups generated by AI based on today's CYTK price and gamma walls.
